Irina Khrebtukova

Illumina (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index14.4kcitations63works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Associations and Epidemiology(16), Bioinformatics and Genomic Networks(16), Statistical Methods in Clinical Trials(12), RNA Research and Splicing(11), Molecular Biology Techniques and Applications(9)

Publications62 total

DNA reference reagents isolate biases in microbiome profiling: a global multi-lab study
mSystems·2025· 4 citedOpen Access
Supplementary Table S1 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Figure 1 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S3 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S2 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S5 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S4 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S7 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S3 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S1 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S5 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S4 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S2 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S6 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Data from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Figure 1 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S7 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Supplementary Table S6 from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Data from Evidence for the Presence of Disease-Perturbed Networks in Prostate Cancer Cells by Genomic and Proteomic Analyses: A Systems Approach to Disease
2023Open Access
Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells
Nature Communications·2022· 42 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Gary P. Schroth(24), Shujun Luo(22), Daixing Zhou(13), Thomas J. Vasicek(10), Biaoyang Lin(8), James T. White(8), Angelita G. Utleg(8), Eugene C. Yi(8), Paul Shannon(8), Paul H. Lange(8), David R. Goodlett(8), Leroy Hood(8), Wei Lü(7), Xiaowei Yan(7), Robin Li(6), Mahendra S. Rao(5), Tao Xie(5), Rickard Sandberg(4), Lu Zhang(4), Takumi Miura(4)